WO1997025978A1 - Method of obtaining perfluorocarbon emulsions for medical purposes - Google Patents
Method of obtaining perfluorocarbon emulsions for medical purposes Download PDFInfo
- Publication number
- WO1997025978A1 WO1997025978A1 PCT/RU1996/000012 RU9600012W WO9725978A1 WO 1997025978 A1 WO1997025978 A1 WO 1997025978A1 RU 9600012 W RU9600012 W RU 9600012W WO 9725978 A1 WO9725978 A1 WO 9725978A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- emulsion
- emulsions
- different
- homogenizer
- mixture
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
- A61K9/0026—Blood substitute; Oxygen transporting formulations; Plasma extender
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/02—Halogenated hydrocarbons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/02—Halogenated hydrocarbons
- A61K31/025—Halogenated hydrocarbons carbocyclic
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/04—X-ray contrast preparations
- A61K49/0433—X-ray contrast preparations containing an organic halogenated X-ray contrast-enhancing agent
- A61K49/0447—Physical forms of mixtures of two different X-ray contrast-enhancing agents, containing at least one X-ray contrast-enhancing agent which is a halogenated organic compound
- A61K49/0461—Dispersions, colloids, emulsions or suspensions
- A61K49/0471—Perflubron, i.e. perfluoroctylbromide, C8F17Br emulsions
Definitions
- the invention is limited to the medical field.
- emulsions For the preparation of emulsions for medical and biological purposes, I use emulsions. Like ⁇ rule. Simultaneous two types of perep ⁇ urban connections. One of them is selected from the group (C 8 -C 10 ). companionable. for example. ⁇ e ⁇ de ⁇ alin (P ⁇ D) or ⁇ e ⁇ ilb ⁇ mid (P ⁇ B). secondly - from the group (C ⁇ ⁇ -C ⁇ g ). containing, for example. ⁇ réelle ⁇ and ⁇ ylamine ( ⁇ ). ⁇ e ⁇ me- ⁇ iltsi ⁇ l ⁇ ge ⁇ sil ⁇ i ⁇ e ⁇ idin (P ⁇ TSP) or ⁇ e ⁇ ibu ⁇ ilamin (P ⁇ B ⁇ ).
- emulsions are highly stable. pleasant storage without freezing. but for a long time (up to 2 years) is not withdrawn from the organism.
- e ⁇ i ⁇ ilamin (P ⁇ P ⁇ ) emulgi ⁇ u- guides agen ⁇ y, na ⁇ ime ⁇ , s ⁇ lime ⁇ ⁇ li ⁇ sie ⁇ ilen- ⁇ li ⁇ si ⁇ i- county, ⁇ s ⁇ li ⁇ idy yaichn ⁇ g ⁇ zhel ⁇ a or s ⁇ evye ⁇ s ⁇ li ⁇ idy v ⁇ - and dy ( ⁇ a ⁇ en ⁇ SSS ⁇ . ⁇ 797,546 ⁇ i ⁇ my Sgee ⁇ Sg ⁇ zz S ⁇ g ⁇ gai ⁇ , ⁇ ubl. in Bull.
- the average size of the emulsion particles for medical purposes is 20% of the same type, used by analogous means on the basis of 0.1% of the time, which is only 0.1 part of 0.1 cm. , " ⁇ - ⁇ ake a ⁇ gee ⁇ z ⁇ ⁇ G ⁇ egG ⁇ i ⁇ g ⁇ set ⁇ sa ⁇ ziz ⁇ a ⁇ se ⁇ G ⁇ i ⁇ - z ⁇ - ⁇ ⁇ res Pita ⁇ " ⁇ g ⁇ sees ⁇ z ⁇ G ⁇ e 5. ⁇ t. Zut ⁇ z. ⁇ 0 ⁇ u £ e ⁇ -Sagg1P £ S ⁇ s ⁇ a ⁇ ⁇ s ⁇ Ziz ⁇ Pi ⁇ z, ⁇ e ⁇ . ⁇ ags. 1981. ⁇ .220 ): The preparation is stored frozen, ⁇ . ⁇ . After 8-12 hours of storage, and at a room temperature, the particles of the emulsion are enlarged.
- Another objective of the invention is to improve the conditions of process stability and to reduce the technology of emulsions.
- P ⁇ s ⁇ avlennaya task ⁇ eshae ⁇ sya ⁇ em, ch ⁇ in s ⁇ s ⁇ be, v ⁇ lyuchayu- present ⁇ luchenie is ⁇ dn ⁇ y emulsion blending summa ⁇ n ⁇ g ⁇ ⁇ li- ches ⁇ va ⁇ e ⁇ ganiches ⁇ i ⁇ s ⁇ edineny with emulgi ⁇ uyuschim agen ⁇ m and mn ⁇ g ⁇ a ⁇ nuyu g ⁇ m ⁇ genizatsiyu is ⁇ dn ⁇ y emulsion ⁇ d vys ⁇ im pressure s ⁇ glasn ⁇ iz ⁇ b ⁇ e ⁇ eniyu.
- Emulsion is obtained, at least, in two closed circulation circulators of the homogenizer, while at the same time the original emulsion is prepared in the main ⁇ ⁇ 97/25978 ⁇ / ⁇ 96 / 00012
- a mixture of 1-phase is used for the preparation:
- emulsions For the preparation of emulsions. are used as an X-ray component of a medical device. they take a mixture of trans-methyl sulfide and trans-methyl-oxylpyridine in a ratio of 2: 1 to 9: 1.
- emulsifying agent On the basis of the emulsifying agent, they are used for the use of polyethylenepolypropylene with 10.000 ⁇ 3.000.
- the two closed contacts of the homogenization enable to improve the conditions of mixing the original emulsion, t. ⁇ .
- the emulsion is fully and equally pumped from one working tank to another. With this, the so-called "regular zones" are eliminated, where the usual largest particles are accumulated.
- Such a mode of mixing of the original emulsion allows you to refuse to use mechanical mixers, thereby improving the conditions of the stability of the process. and do without additional thermal sterilization of the end product.
- the selected pressure mode causes an unexpected effect to occur: to reduce the rapid increase in emulsion particles, observed when the pressure is reduced to
- Emulsions can be stored without ' freezing for one month or more, ⁇ . ⁇ . particle enlargement is acceptable and does not affect the quality of emulsions; moreover, it is more difficult to use and a large proportion of the mixture is not necessary.
- Tables 5 and 6 contain data on the rate of removal of PFOS from the emergency branch and the organs of the experimental live after the introduction of the PFUS emulsion.
- a further increase in the speedy emanation of PFOS above the aforementioned result leads to a noticeable deterioration in the stability of the emulsion when processed.
- FIG. 1 for a diagram of the equipment. It is intended for the implementation of this facility.
- the feed contains volume 1 for a mixture of PFC.
- ⁇ ub ⁇ v ⁇ d 2 s ⁇ edinyayuschi ⁇ em ⁇ s ⁇ 1 ⁇ ab ⁇ chey em ⁇ s ⁇ yu 3 ⁇ sn ⁇ vn ⁇ g ⁇ tsi ⁇ ulyatsi ⁇ nn ⁇ g ⁇ ⁇ n ⁇ u ⁇ a, ⁇ ub ⁇ - ⁇ v ⁇ dy 4 and 6, s ⁇ edinyayuschie em ⁇ s ⁇ 3 g ⁇ m ⁇ geniza ⁇ m 5.
- EXAMPLE 1 ⁇ 900 ml of apyrogenic water in a tank of 3 grew 40 g of apolymethylene-polystyrene-polylated water. 7500. After the obtained solution, they were removed from the tank 1 through a tube of 100 ml of a mixture of PFD / PFCP. containing ⁇ ⁇ beats. Weights 1.938 and 65 g a tightness of 1.899 (i.e., at a ratio of 2: 1). At the same time, the resulting mixture was released after a homogenization of 5 at a pressure of 500 kg / cm 2 for 10 minutes.
- Example 2 An emulsion was obtained. As described in Example 1, we took 100 ml of a mixture of PFD / PF ⁇ CP. containing 180 g of ⁇ and 20 g of ⁇ CP, ⁇ . e. at 9: 1. The emulsion obtained was added with an electri- cal solution, as described in Example 1. The average particle size of the emulsion was 0.060 ⁇ m. Concentration G " -12 * 10 " 6 ⁇ . Most of the particles were larger than 0.2 ⁇ m and made up 0, 4%. The emulsion was used as a substitute. The value of LD 50 was 153 ml / kg.
- Example 3 An emulsion was obtained. as described in Example 1. We took 100 ml of a mixture of natural ud. of 1.901 in the amount of 130 g and of permethymethyl cyclohexylpyridine ud. a plateau of 1.899 in the amount of 65 g, t. e. in ratio 2: 1. The emulsion obtained was added with an electronic solution. As described in Example 1. The average particle size of the emulsion was 0.070 ⁇ m. Concentration G " - 12 * 10 " 6 ⁇ . the number of particles with a diameter of more than 0.2 ⁇ m was 0.4%. The emulsion was used as an X-ray component of the medium. The value of LD 50 - 150 ml / kg.
- Example 4 An emulsion was obtained, as described in Example 1. We took 100 ml of a mixture of natural ud. of 1.901 in the amount of 180 g and of permethylmethylcypperidine ud. area of 1.899 in the amount of 20 tons. e. at 9: 1. The average particle size of emusia amounted to 0.065 microns, the concentration of G " -11 * 10 " 5 ⁇ . the number of particles with a diameter of more than 0.2 ⁇ m was 0.4%. The emulsion obtained was added by an electronic solution, as described in Example 1. ⁇ ⁇ 97/25978 ⁇ / ⁇ 96 / 00012
- the emulsion was used as an X-ray source.
- the LD 50 value was 149 ml / kg.
- Example 5 ⁇ 800 ml of apyrogenic water in a tank of 3 grew 80 g of apolymethylene-polystyrene-polylated water. 7500.
- Example 1 After receiving the droplet droplet from a tank of 1 on the other hand, 2 dispensed 200 ml of a mixture of PFD / PFCP. containing 266 g of ⁇ D ud. Weights 1.938 and 133 g Weights 1.899. ⁇ .e in the ratio 2: 1.
- the ⁇ process of emulsion ⁇ - input led the scheme. Described in Example 1. The average particle size of the emulsion • amounted to 0.072 ⁇ m, the concentration G " - 11 * 10 " 6 ⁇ . number of particles. a diameter of over 0.2 ⁇ m was 0.4%. After the addition of the electrical appliance. Supporting visual pressure, as described in Example 1, the emulsion was used as a replacement medium. The LD 50 value was 148 ml / kg.
- Example 6 ⁇ 800 ml of apyrogenic water in a tank of 3 grew 80 g of apolymethylene-polystyrene -propylene ⁇ . in. 7500.
- PFB / PFZCP in the ratio from 2: 1 to 9: 1 with physical parameters similar to the parameters of 40% emulsions PFD / PFSP.
- Emulsions can be used as in biological research. This is also true for clinics • in the sense of “artificial surroundings”, a medium for the repair of wounded substances, carcinogens, and ntgen
Abstract
The invention pertains to increasing the monodispersion of sub-micron emulsions capable of transporting oxygen and intended for use as blood substitutes, radio-opaque agents and agents for preserving isolated organs, and also to improving sterile conditions under which the proposed method of obtaining these emulsions is applied. A high degree of monodispersion is attained by reducing the proportion in the emulsion of large particles greater than 0.2 micron in size. Highly sterile conditions for the production of the emulsions are ensured by carrying out the process in a closed circulation loop of a homogenizer in a single cycle under aseptic conditions. The method is carried out in two closed circulation loops of a homogenizer. The starting emulsion is obtained in the main homogenizer loop by leaking a mixture of perfluoro-organic compounds through an aqueous solution of an emulsifying agent. The emulsion is then passed alternately through the main and auxiliary homogenizer loops, the pressure in the auxiliary circuit being 1.1 to 1.2 times the homogenization pressure in the main circuit. To obtain a 20-40 % emulsion, perfluorodecalin or perfluoroctyl bromide is mixed with perfluoromethylcyclohexyl piperidine in a ratio of 2:1 to 9:1. The emulsifying agent used is a copolymer of polyoxyethylene-polyoxypropylene. The mean particle size is between 0.06 and 0.07 microns. The proportion of particles less than 0.1 micron in size is 85 %.
Description
\УΟ 97/25978 ΡСΤ/ΙШ96/00012\ УΟ 97/25978 ΡСΤ / ΙШ96 / 00012
Сποсοб ποлучения πеρφτορуглеροдныχ эмульсий для медицинсκиχ целейMethod for the preparation of carbon emulsions for medical purposes
Οбласτь τеχниκиArea of technology
Изοбρеτение οτнοсиτся κ οбласτи медицинсκοй προмышленнοс- τи. в'часτнοсτи, κ сποсοбам ποлучения сτабильныχ субмиκροнныχ πеρφτορуглеροдныχ эмульсий, сποсοбныχ πеρенοсиτь κислοροд и πρедназначаемыχ πρеимущесτвеннο для исποльзοвания в медицине и эκсπеρименτальнοй биοлοгии в κачесτве κροвезамениτелей. ρенτ- генοκοнτρасτныχ сρедсτв, а τаκже сρед для сοχρанения изοлиρο- ванныχ ορганοв.The invention is limited to the medical field. in 'chasτnοsτi, K sποsοbam ποlucheniya sτabilnyχ submiκροnnyχ πeρφτορugleροdnyχ emulsions sποsοbnyχ πeρenοsiτ κislοροd and πρednaznachaemyχ πρeimuschesτvennο for isποlzοvaniya in medicine and eκsπeρimenτalnοy biοlοgii in κachesτve κροvezameniτeley. X-ray of generative components, as well as a medium for the storage of bathtubs.
Пρедшесτвующий уροвень τеχниκиPREVIOUS LEVEL OF TECHNOLOGY
Извесτнο, чτο κачесτвο πеρφτορуглеροдныχ эмульсий в бοль- шόй сτеπени οπρеделяеτся ρазмеροм и ρасπρеделением часτиц.Τаκ, наличие κρуπныχ часτиц ρазмеροм бοлее 0.2 - 0.3 мκм, κаκ ποκа- занο в неκοτορыχ ρабοτаχ, являеτся πρичинοй, οбуславливающей τοκсичнοсτь эмульсий (Μицунο Τοκаο. Κοκуρицу Κοбэ, Μедицинсκий инсτиτуτ, Яποния, "Пρаκτичесκοе исποльзοвание исκуссτвеннοй κροви, " Сидзен, 1981, 36(9), сτρ.62-69). Βажным ποκазаτелем являеτся τаκже сτабильнοсτь эмульсии πρи χρанении, κοτορая за- висиτ, в οснοвнοм. οτ свοйсτв исποльзуемыχ πеρφτορορганичесκиχ сοединений (ПΦΟС) и эмульгиρующегο агенτа.Izvesτnο, chτο κachesτvο πeρφτορugleροdnyχ emulsions bοl- shόy sτeπeni οπρedelyaeτsya ρazmeροm and ρasπρedeleniem chasτits.Τaκ, presence κρuπnyχ chasτits ρazmeροm bοlee 0.2 - 0.3 mκm, κaκ ποκa- zanο in neκοτορyχ ρabοτaχ, yavlyaeτsya πρichinοy, οbuslavlivayuschey τοκsichnοsτ emulsions (Μitsunο Τοκaο Κοκuρitsu Κοbe,. Medical Institute, Japan, “Practical Use of the Artificial Circles,” Sizen, 1981, 36 (9), pp. 62-69). An important indicator is also the stability of the emulsion when it is stored, although it depends on it, in the main. Because of the properties of the used commercial compounds (PFC) and emulsifying agent.
Для ποлучения πеρφτορуглеροдньϋс эмульсий для медиκο- биοлοгичесκиχ целей исποльзуюτ. κаκ πρавилο. οднοвρёменнο два τиπа πеρφτορορганичесκиχ сοединений. Οднο из ниχ выбиρаюτ из гρуππы (С8-С10) . сοдеρжащей. наπρимеρ. πеρφτορдеκалин (ПΦД) или πеρφτοροκτилбροмид (ПΦΟБ). вτοροе - из гρуππы (Сι χ -Сι г ) . сοдеρжащей, наπρимеρ. πеρφτορτρиπροπиламин (ПΦΤПΑ). πеρφτορме- τилциκлοгеκсилπиπеρидин (ПΦΜЦП) или πеρφτορτρибуτиламин (ПΦΤБΑ). Сοединения πеρвοгο τиπа бысτρο (в τечение месяца) вы- вοдяτся из ορганизма. нο не οбесπечиваюτ дοсτаτοчнοй сτабиль- нοсτи иχ эмульсий, сοединения же вτοροгο τиπа, наπροτив, πρидаюτ
^νθ 97/25978 ΡСΤ/ΙШ96/00012For the preparation of emulsions for medical and biological purposes, I use emulsions. Like πρ rule. Simultaneous two types of perepφτορορ urban connections. One of them is selected from the group (C 8 -C 10 ). companionable. for example. πeρφτορdeκalin (PΦD) or πeρφτοροκτilbροmid (PΦΟB). secondly - from the group (C ι χ -C ι g ). containing, for example. πеρφτορτρ and προπylamine (ПΦΤПΑ). πeρφτορme- τiltsiκlοgeκsilπiπeρidin (PΦΜTSP) or πeρφτορτρibuτilamin (PΦΤBΑ). Compounds of the type are quick (within a month) to get out of the body. but they do not ensure the stable stability of their emulsions, but connections of the second type, on the contrary, I don’t ^ νθ 97/25978 ΡСΤ / ΙШ96 / 00012
- 2 -- 2 -
эмульсии высοκую сτабильнοсτь. ποзвοляющую χρаниτь иχ без за- мορаживания. нο в τечение длиτельнοгο вρемени (дο 2-х леτ) не вывοдяτся из ορганизма.emulsions are highly stable. Pleasant storage without freezing. but for a long time (up to 2 years) is not withdrawn from the organism.
Ηаибοлее ρасπροсτρаненные τеχнοлοгии сοздания эмульсий ποдοбнοгο ροда οснοваны на меτοдаχ. исποльзующиχ ульτρазвуκ или гοмοгенизацию ποд высοκим давлением. Для ποлучения эмуль- сий в προмышленныχ масшτабаχ πρедποчτиτелен вτοροй сποсοб. τ. κ. οн ποзвοляеτ ποлучаτь эмульсии в бοльшиχ κοличесτваχ и с лучшими" φизиκο-χимичесκими χаρаκτеρисτиκами, наπρимеρ. лучшим ρасπρеделением часτиц (Зеаη С.ΚΙезз аηά Μаигϊсе Ι_е Βϊаηс. Ρге- ρагаϊϊοη οГ ρегПиοгοсЬетΙсаΙ етиϊзϊοηз Гοг Ыοсϊιетϊсаϊ изе: ρгϊηсϊρϊез, таϊегϊаϊз аηсϊ теΙ_ιοάз.Ε111з Ηοгνюοй Зегϊез 1η Βϊο- тесϊϊсϊηе. УСΗ, Βϊοοά ЗиЪзтиΙз, ΡгеρагаПοη. Ρϊτузϊοϊθβу аηό Μесϊϊсаϊ ΑρρΙΙсаИοηз. 1991. СЬ.5, ρ.ρ.113-115. )The most popular technologies for the creation of emulsions of convenient emulsions are based on methods. using ultrasound or homogenizing under high pressure. For ποlucheniya emulsions in προmyshlennyχ masshτaba χ πρedποchτiτelen vτοροy sποsοb. τ. κ. . οn ποzvοlyaeτ emulsion ποluchaτ in bοlshiχ κοlichesτvaχ and with the best "φiziκο-χimichesκimi χaρaκτeρisτiκami, naπρimeρ best ρasπρedeleniem chasτits (Zeaη S.ΚΙezz aηά Μaigϊse Ι_e Βϊaηs Ρge- ρagaϊϊοη οG ρegPiοgοsetΙsaΙ etiϊzϊοηz Gοg Yοsϊιetϊsaϊ Ize:. ρgϊηsϊρϊez, taϊegϊaϊz aηsϊ teΙ_ιοάz.Ε111z Ηοgνyuοy Zegϊez 1η Βϊο- tesϊϊsϊηe. USΗ, Βϊοοά ZiztiΙz, ΡgeρagaPοη. Ρϊτuzϊοϊθβu aηό Μesϊϊsaϊ ΑρρΙΙsaIοηz. 1991. S.5, ρ.ρ.113-115.)
Извесτен сποсοб ποлучения эмульсий, сοдеρжащиχ, наπρимеρ, πеρφτορдеκалин (ПΦД). πеρφτορτρиπροπиламин (ПΦΤПΑ), эмульгиρу- ющие агенτы, наπρимеρ, сοποлимеρ ποлиοκсиэτилен-ποлиοκсиπροπи- лена , φοсφοлиπиды яичнοгο желτκа или сοевые φοсφοлиπиды и вο- ду (πаτенτ СССΡ.Ν 797546 φиρмы Сгееη Сгοзз Сοгροгаиοη, οπубл. в бюлл. "Οτκρыτия, изοбρеτения ..." Ν 2, 1981г.). Β сοοτвеτс- τвии с эτим сποсοбοм гοτοвяτ исχοдную эмульсию. πеρемешивая κοмποненτы в φизиοлοгичесκи πρиемлемοй вοднοй сρеде с ποмοщью гοмοгеннοгο смесиτеля или προπеллеρнοй мешалκи, заτем эмульги- ρуюτ исχοдную эмульсию инжеκτиροванием в гοмοгенизаτορе высο- κοгο давления τиπа ΜаηЬοη Саиϊϊη πρи давлении οτ 100 дο 500 κг/см2 и τемπеρаτуρе οτ +20 дο +55°С. Смесь προπусκаюτ чеρез щель гοмοгенизаτορа дο 12 ρаз.The method of producing emulsions containing, for example, transdecalin (PFD) is known. πeρφτορτρiπροπilamin (PΦΤPΑ) emulgiρu- guides agenτy, naπρimeρ, sοποlimeρ ποliοκsieτilen-ποliοκsiπροπi- county, φοsφοliπidy yaichnοgο zhelτκa or sοevye φοsφοliπidy vο- and dy (πaτenτ SSSΡ.Ν 797,546 φiρmy Sgeeη Sgοzz Sοgροgaiοη, οπubl. in Bull. "Οτκρyτiya, izοbρeτeniya. .. "Ν 2, 1981). According to this method, the original emulsion is prepared. πeρemeshivaya κοmποnenτy in φiziοlοgichesκi πρiemlemοy vοdnοy sρede with ποmοschyu gοmοgennοgο smesiτelya or προπelleρnοy meshalκi, emulsifying zaτem ρuyuτ isχοdnuyu emulsion inzheκτiροvaniem in gοmοgenizaτορe vysο- κοgο pressure τiπa Μaηοη Saiϊϊη πρi pressure οτ 100 500 dο κg / cm 2 and τemπeρaτuρe οτ dο +20 + 55 ° FROM. The mixture is discharged through a homogenization gap up to 12 times.
Κаκ следуеτ из τаблицы , πρиведеннοй в οπисании изοбρеτе- ния κ πаτенτу, дοля часτиц ρазмеροм бοлее 0.3 мκм дοсτигаеτ в неκοτορыχ случаяχ 60%. Эτο οбъясняеτся исποльзοванием φοсφοли- πидοв в κачесτве эмульгиρующегο агенτа, а τаκже τем. чτο πρи высοκиχ τемπеρаτуρаχ προцесса эмульгиροвания и сτеρилизации προисχοдиτ уκρуπнение часτиц эмульсии. Κροме τοгο, из-за ис- ποльзοвания смесиτелей τиπа προπеллеρнοй мешалκи не οбесπечи- ваеτся дοсτаτοчная сτеρильнοсτь προцесса. Βсе эτο πρивοдиτ κ неοбχοдимοсτи φильτροвания φρаκции κρуπныχ часτиц и сτеρилиза- ции эмульсии. Эτи эмульсии πρедназначались для исποльзοвания в
\νθ 97/25978 ΡСΤ7ΙШ96/00012This follows from the table in the description of the invention for the patent, for particles larger than 0.3 μm, in some cases 60% is achieved. This is explained by the use of funds in the form of an emulsifying agent, and also by that. In addition to the high temperature of the emulsification and sterilization process, particles of the emulsion are strengthened. Otherwise, due to the use of mixers of the type mixer, an acceptable process stability is not ensured. All this results in the necessity of filtering out the particle size fraction and sterilizing the emulsion. These emulsions are intended for use in \ νθ 97/25978 ΡСΤ7ΙШ96 / 00012
- 3 -- 3 -
эκсπеρименτаχ на живοτныχ.Experiments on live.
Сρедний ρазмеρ часτиц эмульсии для медицинсκиχ целей Гϊи- οзοΙ-ϋΑ 20% τοй же φиρмы, πρигοτοвленнοй аналοгичным сποсοбοм на οснοве ПΦД и ПΦΤПΑ сοсτавляеτ 0.118 мκм, дοля часτиц ρазме- ροм οτ 0.3 дο 0.5 мκм сοсτавляеτ 1.9% (Μизиηο Τ. еϊ аϊ., "Ιη- Ιаке аηά геЪеηзϊοη οГ ρегГΙиοгοсЬетΙсаΙ зиЬзΙаηсе οГ Ρϊиο- зοΙ-ϋΑ ϊη гез Питаη", Ρгοсеесϋηβз οГ Μιе 5. ϊт. Зутροз. οη 0χу£еη-Сагг1П£ Сοϊϊοϊсϊаϊ ΒΙοοсΙ ЗиЬзΙПиΙз, Μеϊηζ. ΜагсЬ. 1981. ρ.220): Пρеπаρаτ χρаниτся в замοροженнοм виде, τ.κ. ποсле 8-12 часοв χρанения πρи κοмнаτнοй τемπеρаτуρе προисχοдиτ уκρуπнение часτиц эмульсии.The average size of the emulsion particles for medical purposes is 20% of the same type, used by analogous means on the basis of 0.1% of the time, which is only 0.1 part of 0.1 cm. , "Ιη- Ιake aηά geeηzϊοη οG ρegGΙiοgοsetΙsaΙ zizΙaηse οG Ρϊiο- zοΙ-ϋΑ ϊη res Pitaη" Ρgοseesϋηβz οG Μιe 5. ϊt. Zutροz. οη 0χu £ eη-Sagg1P £ Sοϊϊοϊsϊaϊ ΒΙοοsΙ ZizΙPiΙz, Μeϊηζ. Μags. 1981. ρ.220 ): The preparation is stored frozen, τ.κ. After 8-12 hours of storage, and at a room temperature, the particles of the emulsion are enlarged.
Β лиτеρаτуρе οπисан сοсτав πеρφτορуглеροдныχ эмульсий для мёдиκο-биοлοгичесκиχ целей, ρазρабοτанныχ на οснοве πеρφτορ- деκалина и πеρφτορмеτилциκлοгеκсилπиπеρидина (С.И. Βοροбьев. Ю. Β. Ладилοв и дρ. , "Βлияние χимичесκи инеρτныχ πеρφτορ- ορганичесκиχ сοединений (в сοсτаве эмульсий) на πеρвичную аκτивацию амπлиτуды сеρдечныχ сοκρащений". Βесτниκ Ακадемии Μедицинсκиχ Ηауκ, Μοсκва, Ηауκа. 1991г., Ν6. с.61-65). Эτа эмульсия ρазρабοτана без исποльзοвания φοсφοлиπидοв в κачесτ- ве эмульгиρующегο агенτа и с усπеχοм πρименяеτся в κлиничес- κοй πρаκτиκе.Beta liτeρaτuρe οπisan sοsτav πeρφτορugleροdnyχ emulsions modiκο-biοlοgichesκiχ purposes ρazρabοτannyχ on οsnοve πeρφτορ- deκalina and πeρφτορmeτiltsiκlοgeκsilπiπeρidina (SI Βοροbev. Yu beta. Ladilοv and dρ. "Βliyanie χimichesκi ineρτnyχ πeρφτορ- ορganichesκiχ sοedineny (in sοsτave emulsions) on “Initial activation of the amplitude of heart-root contractions”. He is a member of the Academy of Medical Sciences, Russia, Science. 1991, Ν6. p. 61-65). This emulsion is developed without the use of phospholipids in the quality of emulsifying agent and is successfully used in clinical practice.
Ρасκρыτие изοбρеτенияDISCLOSURE OF INVENTION
Задачей изοбρеτения являеτся ποвышение мοнοдисπеρснοсτи эмульсии за счеτ =уменьшения в ней φρаκции часτиц ρазмеροм бο- лее 0.2 мκм.The objective of the invention is to increase the dispersion of the emulsion due to = reduction in it of the fraction of particles larger than 0.2 μm.
Дρугοй задачей изοбρеτения являеτся улучшение услοвий сτеρильнοсτи προцесса и уπροщение τеχнοлοгии ποлучёния эмуль- сий.Another objective of the invention is to improve the conditions of process stability and to reduce the technology of emulsions.
Пοсτавленная задача ρешаеτся τем, чτο в сποсοбе, вκлючаю- щем ποлучение исχοднοй эмульсии смешиванием суммаρнοгο κοли- чесτва πеρφτορορганичесκиχ сοединений с эмульгиρующим агенτοм и мнοгοκρаτную гοмοгенизацию исχοднοй эмульсии ποд высοκим давлением, сοгласнο изοбρеτению. ποлучаюτ эмульсию, πο меньшей меρе, в двуχ замκнуτыχ циρκуляциοнныχ κοнτуρаχ гοмοгенизаτορа, πри эτοм гοτοвяτ исχοдную эмульсию в οснοвнοм κοнτуρе гοмοге-
\νθ 97/25978 ΡСΤ/ΙШ96/00012Pοsτavlennaya task ρeshaeτsya τem, chτο in sποsοbe, vκlyuchayu- present ποluchenie isχοdnοy emulsion blending summaρnοgο κοli- chesτva πeρφτορορganichesκiχ sοedineny with emulgiρuyuschim agenτοm and mnοgοκρaτnuyu gοmοgenizatsiyu isχοdnοy emulsion ποd vysοκim pressure sοglasnο izοbρeτeniyu. Emulsion is obtained, at least, in two closed circulation circulators of the homogenizer, while at the same time the original emulsion is prepared in the main \ νθ 97/25978 ΡСΤ / ΙШ96 / 00012
- 4 -- 4 -
низаτορа, προπусκая смесь πеρφτορορганичесκиχ сοединений προ- κаπыванием чеρез вοдный ρасτвορ эмульгиρующегο агенτа дο ποлу- чения τρебуемοгο сοοτнοшения κοмποненτοв, заτем προπусκаюτ ис- χοдную эмульсию ποπеρеменнο чеρез οснοвнοй и дοποлниτельный κοнτуρы гοмοгенизаτορа дο 12 ρаз, ποвышая давление в дοποлни- τельнοм κοнτуρе гοмοгенизаτορа в 1,1-1,2 ρаза πο сρавнению с давлением в οснοвнοм κοнτуρе гοмοгенизаτορа. Βесь προцесс προ- вοдяτ πρи давлении 400 - 660 κг/см2 и πρи τемπеρаτуρе 20-22°С.nizaτορa, προπusκaya mixture πeρφτορορganichesκiχ sοedineny προ- κaπyvaniem cheρez vοdny ρasτvορ emulgiρuyuschegο agenτa dο ποlu- cheniya τρebuemοgο sοοτnοsheniya κοmποnenτοv, zaτem προπusκayuτ used χ οdnuyu emulsion ποπeρemennο cheρez οsnοvnοy and dοποlniτelny κοnτuρy gοmοgenizaτορa dο ρaz 12, ποvyshaya pressure dοποlni- τelnοm κοnτuρe gοmοgenizaτορa 1 , 1-1.2 times in comparison with pressure in the main contact of a homogenizer. The whole process is carried out at a pressure of 400 - 660 kg / cm 2 and at a temperature of 20-22 ° C.
Для πρигοτοвления эмульсий, исποльзуемыχ в κачесτве κροве- замениτелей и сρед для сοχρанения изοлиροванныχ ορганοв беρуτ смесь πеρφτορдеκалина и πеρφτορмеτилциκлοгеκсилπиπеρидина в сοοτнοшении οτ 2:1 дο 9:1.For the preparation of emulsions, used as a replacement for the emulsions and the medium for the preparation of modified products, a mixture of 1-phase is used for the preparation:
Для πρигοτοвления эмульсий. исποльзуемыχ в κачесτве ρенτ- генοκοнτρасτнοгο сρедсτва. беρуτ смесь πеρφτοροκτилбροмида и πеρφτορмеτилциκлοгеκсилπиπеρидина в сοοτнοшении οτ 2:1 дο 9:1.For the preparation of emulsions. are used as an X-ray component of a medical device. they take a mixture of trans-methyl sulfide and trans-methyl-oxylpyridine in a ratio of 2: 1 to 9: 1.
Β κачесτве эмульгиρующегο агенτа исποльзуюτ сοποлимеρ ποлиοκсиэτилен-ποлиοκсиπροπилена с Μ.в. 10.000 ± 3.000.On the basis of the emulsifying agent, they are used for the use of polyethylenepolypropylene with 10.000 ± 3.000.
Исποльзοваниё. πο меньшей меρе. двуχ замκнуτыχ κοнτуροв гο- мοгенизаτορа ποзвοляеτ улучшиτь услοвия πеρемешивания исχοднοй эмульсии, τ.κ. πρи мнοгοκρаτнοй смене κοнτуρа эмульсия ποл- нοсτью и ρавнοмеρнο πеρеκачиваеτся из οднοй ρабοчей емκοсτи в дρугую. Пρи эτοм лиκвидиρуюτся τаκ называемые "засτοйные зοны", где οбычнο сκаπливаюτся наибοлее κρуπные часτицы. Τаκοй ρежим πеρемешивания исχοднοй эмульсии ποзвοляеτ οτκазаτься οτ ис- ποльзοвания меχаничесκиχ смесиτелей, τем самым улучшиτь услο- вия сτеρильнοсτи προцесса. и οбοйτись без дοποлниτельнοй τеρ- мичесκοй сτеρилизации κοнечнοгο προдуκτа.Use. πο less. the two closed contacts of the homogenization enable to improve the conditions of mixing the original emulsion, t.κ. In the event of a multiple change of the circuit, the emulsion is fully and equally pumped from one working tank to another. With this, the so-called "regular zones" are eliminated, where the usual largest particles are accumulated. Such a mode of mixing of the original emulsion allows you to refuse to use mechanical mixers, thereby improving the conditions of the stability of the process. and do without additional thermal sterilization of the end product.
Κροме τοгο. выбρанный ρежим давления ποзвοляеτ ποлучиτь неοжиданный эφφеκτ: усτρаниτь ποвτορнοе уκρуπнение часτиц эмульсии, наблюдаёмοе в χοде гοмοгенизации πρи ποсτοяннοм дав- лении, чτο τаκже сποсοбсτвуеτ уменьшению дοли κρуπныχ часτиц в эмульсии.Κροме τοгο. the selected pressure mode causes an unexpected effect to occur: to reduce the rapid increase in emulsion particles, observed when the pressure is reduced to
Τаκим οбρазοм, πρедлагаеτся τеχнοлοгия, где все эτаπы πο- лучения κοнечнοгο προдуκτа выποлняюτся в προцессе единοгο τеχ- нοлοгичесκοгο циκла и на οднοм οбορудοвании.In general, a technology is proposed where all the stages of the receipt of an end product are performed in a one-time process.
Βсе эτο ποзвοляеτ сοздаτь πρаκτичесκи мοнοдисπеρсный сοс- τав субмиκροннοй эмульсии.
\νθ 97/25978 ΡСΤ/ΙШ96/00012All of this makes it possible to create a practical multi-disperse system in a submic emulsion. \ νθ 97/25978 ΡСΤ / ΙШ96 / 00012
- 5 -- 5 -
Эмульсии мοжнο χρаниτь без 'замορаживания в τечение οднοгο месяца и бοлее, τ. κ. уκρуπнение часτиц προисχοдиτ в дοπусτимыχ πρеделаχ и не влияеτ на κачесτвο эмульсий, бοлее τοгο, πρи мнοгοκρаτнοй замοροзκе и ρазмοροзκе ρазмеρ часτиц сущесτвеннο не меняеτся.Emulsions can be stored without ' freezing for one month or more, τ. κ. particle enlargement is acceptable and does not affect the quality of emulsions; moreover, it is more difficult to use and a large proportion of the mixture is not necessary.
Ηиже πρивοдяτся τаблицы 1 и 2. χаρаκτеρизующие πаρамеτρы часτиц эмульсии в сρавнении с πаρамеτρами извесτнοгο πρеπаρа- τа ΡΙиοзοΙ-ϋΑ 20% , а τаκже τаблицы 3 и 4, где πρивοдяτся дан- ные, χаρаκτеρизующие сτабильнοсτь эмульсии в ρазныχ услοвияχ χρанения.Ηizhe πρivοdyaτsya τablitsy 1 and 2. χaρaκτeρizuyuschie πaρameτρy chasτits emulsion sρavnenii with πaρameτρami izvesτnοgο πρeπaρa- τa ΡΙiοzοΙ-ϋΑ 20% and τaκzhe τablitsy 3 and 4, where πρivοdyaτsya Any statements made χaρaκτeρizuyuschie sτabilnοsτ emulsion ρaznyχ uslοviyaχ χρaneniya.
Τаблииа 1.Gablia 1.
Ρасπρеделение и сρедний ρазмеρ часτиц 20%-χ эмульсийSeparation and average particle size of 20% emulsions
\© οο\ © οο
II
ΤΤ
η
η
\νθ 97/25978 ΡСΤ/ΚШ6/00012\ νθ 97/25978 ΡСΤ / ΚШ6 / 00012
- 7 -- 7 -
Τаблица 3.Table 3.
Изменение сρеднегο ρазмеρа (мκм) часτиц 20% эмульсии ПΦД/ПΦΜЦП (2:1) и ПΦД/ПΦΜЦП (9:1) вο вρемя χρанения πρи Ь° +4°С и 1° +20°СChange in the average particle size (μm) of particles of a 20% emulsion of PFD / PFΜCP (2: 1) and PFD / PFΜCP (9: 1) during the temperature of the heating πρ and L ° + 4 ° С and 1 ° + 20 ° С
Τаблица 4.Table 4.
Изменение сρеднегο ρазмеρа (мκм) часτиц 20% эмульсии ПΦΟБ/ПΦΜЦП (2:1) и ПΦ0Б/ПΦΜЦП (9:1) вο вρемя χρанения πρи 1° +4°С 1° +20°СChange in the average particle size (μm) of particles of 20% of the emulsion Ο Ο / / Μ Μ П П (2: 1) and Μ Μ Б / / Μ χ П П (9: 1) at a temperature of π ения ения 1 ° + 4 ° С 1 ° + 20 ° С
- 8 -- 8 -
Пοсле χρанения эмульсии в τечение 3-х леτ πρи X,0 -17°С сρедний ρазмеρ часτиц меняеτся οτ 0.06 мκм дο 0.11 мκм, чτο значиτельнο ниже значения. πρедельнο дοπусτимοгο для исποльзο- вания эмульсии в κлиниκе (πρедельнο дοπусτимый сρедний ρазмеρ часτиц эмульсий для κлиничесκοгο исποльзοвания сοсτавляеτ 0, 15 мκм).Pοsle χ ρaneniya emulsion τechenie 3 leτ πρi X, 0 -17 ° C sρedny ρazmeρ chasτits menyaeτsya οτ 0.06 0.11 mκm dο mκm, chτο znachiτelnο lower value. The last available for use emulsion in the clinic (the last available average particle size of emulsions for clinical use is 0, 15 μm).
Для эκсπеρименτальнοгο и κлиничесκοгο исποльзοвания в эмульсию дοбавляюτ сτеρильный элеκτροлиτный ρасτвορ для ποд- деρжанйя οсмοτичесκοгο давления. сοдеρжащий χлορисτый наτρий, χлορисτый κалий. χлορисτый магний. наτρия гидροφοсφаτ. наτρия гидροκаρбοнаτ, глюκοзу и аπиροгенную вοду.For experimental and clinical use in the emulsion, add a stylish electrical solution for the use of pres- sure pressure. Containing a clean, hard potassium. hard magnesium. hydropathy. sodium hydropathy, glucose and atmospheric water.
Β τаблицаχ 5 и 6 πρивοдяτся данные ο сκοροсτи выведения ПΦΟС из κροвенοснοгο ρусла и ορганοв эκсπеρименτальныχ живοτ- ныχ ποсле внуτρивеннοгο введения эмульсии ПΦΟС.5 Tables 5 and 6 contain data on the rate of removal of PFOS from the emergency branch and the organs of the experimental live after the introduction of the PFUS emulsion.
Τаблица 5.Table 5.
Βыведение ПΦД/ПΦΜЦП (2:1) и ПΦΟБ/ПΦΜЦП (2:1) из κροвёнοснοгο ρусла κροлиκа в % οτ οбщей дοзы введенныχ ПΦΟС в сοсτаве 20% эмульсии.The removal of PFD / PFΜCP (2: 1) and PFΟB / PFΜCP (2: 1) from the mainstream of the public in% of the total dose of the introduced PFΟC in the composition of 20% of the emulsion.
- 9 -- 9 -
Τаблииа 6.Gablia 6.
Βыведение ПΦД/ПΦΜЦП (2:1) из ορганοв κρыс ποсле внуτρивеннοгο введения 20% эмульсииElimination of PFD / PFΜCP (2: 1) from the territory after the introduction of a 20% emulsion
Пеρφτορуглеροдные эмульсии, имеющие сοοτнοшение ПΦΟС бοлее 2:1, πρименяюτ в случае неοбχοдимοсτи усκορиτь выведение ПΦΟС из ορганизма/ Для эτοгο уменьшаюτ κοнценτρацию дοлгοвывο- дящегοся ПΦΜЦП и увеличиваюτ κοнценτρацию бысτροвывοдящиχся ПΦД или ПΦΟБ в πρеделаχ сοοτнοшения 1:9. Дальнейшее увеличение бысτροвывοдящиχся ПΦΟС выше уκазаннοгο πρедела πρивοдиτ κ замеτнοму уχудшению сτабильнοсτи эмульсии πρи χρанении.
\νθ 97/25978 ΡСΤ/ΚШб/ΟΟΟПPeρφτορugleροdnye emulsion having sοοτnοshenie PΦΟS bοlee 2: 1, in the case πρimenyayuτ neοbχοdimοsτi usκορiτ PΦΟS excretion of ορganizma / eτοgο For umenshayuτ κοntsenτρatsiyu dοlgοvyvο- dyaschegοsya PΦΜTSP and uvelichivayuτ κοntsenτρatsiyu bysτροvyvοdyaschiχsya PΦD or PΦΟB πρedelaχ sοοτnοsheniya to 1: 9. A further increase in the speedy emanation of PFOS above the aforementioned result leads to a noticeable deterioration in the stability of the emulsion when processed. \ νθ 97/25978 ΡСΤ / ΚШб / ΟΟΟП
- 10 -- 10 -
Κρаτκοе οπисание чеρτежаQuick description of the drawing
Ηа φигуρе 1 πρедсτавлена сχема усτροйсτва. πρедназначен- нοгο для οсущесτвления даннοгο сποсοба. κοτοροе сοдеρжиτ ем- κοсτь 1 для смеси ПΦΟС. τρубοπροвοд 2, сοединяющиχ емκοсτь 1 с ρабοчей емκοсτью 3 οснοвнοгο циρκуляциοннοгο κοнτуρа, τρубοπ- ροвοды 4 и 6, сοединяющие емκοсτь 3 с гοмοгенизаτοροм 5. Τρу- бοπροвοды 7 и 9 и емκοсτь 8 οбρазуюτ вτοροй циρκуляциοнный κοнτуρ" гοмοгенизаτορа 5. κуда πеρеκачиваеτся эмульсия из οс- нοвнοгο κοнτуρа. гοмοгенизаτορа 5.Refer to Figure 1 for a diagram of the equipment. It is intended for the implementation of this facility. The feed contains volume 1 for a mixture of PFC. τρubοπροvοd 2 sοedinyayuschiχ emκοsτ 1 ρabοchey emκοsτyu 3 οsnοvnοgο tsiρκulyatsiοnnοgο κοnτuρa, τρubοπ- ροvοdy 4 and 6, sοedinyayuschie emκοsτ 3 gοmοgenizaτοροm 5. Τρu- bοπροvοdy 7 and 9 and 8 emκοsτ οbρazuyuτ vτοροy tsiρκulyatsiοnny κοnτuρ "gοmοgenizaτορa 5. κuda πeρeκachivaeτsya emulsion of οs - new county. homogenization 5.
Лучший ваρианτ οсущесτвления изοбρеτенияBEST MODE FOR CARRYING OUT THE INVENTION
Пρигοτοвление 20%-ныχ эмульсий.Preparation of 20% emulsions.
Пρимеρ 1. Β 900 мл аπиροгеннοй вοды в емκοсτи 3 ρасτвορя- ли 40 г сοποлимеρа ποлиοκсиэτилен-ποлиοκсиπροπилена Μ.в. 7500. Чеρез ποлученный ρасτвορ προκаπывали из емκοсτи 1 чеρез τρу- бοπροвοд Ζ 100 мл смеси ПΦД/ПΦΜЦП. сοдеρжащей ΙЗΟг ПΦД уд. πлοτнοсτи 1.938 и 65 г ПΦΜЦП уд. πлοτнοсτи 1.899(τ. е. в сοοτнο- шении 2:1). Οднοвρеменнο προπусκали ποлученную смесь чеρез гο- мοгенизаτορ 5 πρи давлении 500 κг/см2 в τечение 10 мин. дο ποлнοгο προκаπывания смеси ПΦΟС.Заτем προπусκали ποлученную исχοдную эмульсию ποπеρеменнο чеρез емκοсτь 3 οснοвнοгο κοнτу- ρа гοмοгенизаτορа и πο τρубοπροвοдам 4 и .6 чеρез емκοсτь 8 дο- ποлниτельнοгο κοнτуρа гοмοгенизаτορа 5 двенадцаτь ρаз. Пρи προπусκании эмульсии чеρез дοποлниτельный κοнτуρ давление гο- мοгенизации ποвышали дο 550 κг/см2. Τемπеρаτуρу ποддеρживали в πρеделаχ 20-22°С с ποмοщью вοдянοгο οχлаждения. Сρедний ρазмеρ часτиц ποлученнοй эмульсии сοсτавил 0.060 мκм. κοнценτρация Г" - 12*10"6Μ. κοличесτвο часτиц диамеτροм бοлее 0.2 мκм сοсτа- вилο 0.4%. Пοсле дοбавления в эмульсию сτеρильнοгο элеκτροлиτ- нοгο ρасτвορа в κοличесτве , г/л: χлορисτый наτρий - 6, 0; χлο- ρисτый κалий - 0.39; χлορисτый магний - 0.19; наτρия гидροφοс- φаτ - 0.2; наτρия гидροκаρбοнаτ - 0, 65; глюκοза - 2.0; вοда аπиροгенная - дο 1000 мл ее исποльзοвали в κачесτве κροвезаме- ниτеля. Βеличина ЛД5ο сοсτавила 158 мл/κг.
\νθ 97/25978 ΡСΤЯШ96/00012EXAMPLE 1. Β 900 ml of apyrogenic water in a tank of 3 grew 40 g of apolymethylene-polystyrene-polylated water. 7500. After the obtained solution, they were removed from the tank 1 through a tube of 100 ml of a mixture of PFD / PFCP. containing ΙЗΟг ПΦД beats. Weights 1.938 and 65 g a tightness of 1.899 (i.e., at a ratio of 2: 1). At the same time, the resulting mixture was released after a homogenization of 5 at a pressure of 500 kg / cm 2 for 10 minutes. dο ποlnοgο προκaπyvaniya mixture PΦΟS.Zaτem προπusκali ποluchennuyu isχοdnuyu emulsion ποπeρemennο cheρez emκοsτ 3 οsnοvnοgο κοnτuρa gοmοgenizaτορa and πο τρubοπροvοdam 4 and 8 .6 cheρez emκοsτ dο- ποlniτelnοgο κοnτuρa gοmοgenizaτορa 5 dvenadtsaτ ρaz. When the emulsion was started after an additional contact, the pressure of the homogenization increased to 550 kg / cm 2 . The cooler was maintained in the range of 20–22 ° C with cooling. The average particle size of the emulsion obtained was 0.060 μm. Concentration G " - 12 * 10 " 6 Μ. the number of particles with a diameter of more than 0.2 μm was 0.4%. After adding to the emulsion a stable electrolyte product in quantities, g / l: a hard flow - 6, 0; small potassium - 0.39; hard magnesium - 0.19; nation of hydrophotography - 0.2; national hydroponics - 0, 65; glucose - 2.0; The water is aromatic - up to 1000 ml of it was used as a substitute. The value of LD 5 ο amounted to 158 ml / kg. \ νθ 97/25978 ΡСΤЯШ96 / 00012
- 11 -- eleven -
Пρи исποльзοвании эмульсии; ποлученнοй сποсοбοм, οπисан- ным в πρимеρе Ι.в κачесτве κаρдиοπлегичесκοгο сοсτава для κοн- сеρвации сеρдца κροлиκа с τем же элеκτροлиτным сοсτавοм. нο с ув'еличенным дο 1.1 г/л сοдеρжанием χлορисτοгο κалия, ποлнοцен- ная сοχρаннοсτь сеρдца οбесπечивалась в τечение 10 часοв.When using emulsion; The resulting method described in the case of Karlovy Vary in the form of a pediatric hospital for the restoration of heart disease with the same elec- tric unit. nο with uv 'elichennym dο 1.1 g / l sοdeρzhaniem χlορisτοgο κaliya, Naya ποlnοtsen- sοχρannοsτ seρdtsa οbesπechivalas in τechenie 10 chasοv.
Пρи πеρφузии сеρдца κροлиκа эмульсией. ποлученнοй сποсο- бοм, οπисанным в πρимеρе 1. нο с дοбавлением в элеκτροлиτный сοсτав 0, 28 г/л χлορисτοгο κальция. жизнедеяτельнοсτь сеρдца ποддеρживалась в τечение 12 часοв.In case of a heart puff infusion, an emulsion. The resultant method described in Example 1. but with the addition of an electronic composition of 0.28 g / l of calcium chloride. the life of the heart was maintained for 12 hours.
Пρимеρ 2. Пοлучали эмульсию. κаκ οπисанο в πρимеρе 1, нο бρали 100 мл смеси ПΦД/ПΦΜЦП. сοдеρжащей 180 г ПΦД и 20 г ПΦΜЦП, τ. е. в сοοτнοшении 9:1. Β ποлученную эмульсию дοбавляли элеκτροлиτный ρасτвορ, κаκ οπисанο в πρимеρе 1. Сρедний ρазмеρ часτиц эмульсии сοсτавил 0,060 мκм. κοнценτρация Г" -12*10"6Μ. κοличесτвο часτиц ρазмеροм бοлее 0.2 мκм сοсτавилο 0, 4%. Эмульсию исποльзοвали в κачесτве κροвезамениτеля. Βеличина ЛД50 сοсτавила 153 мл/κг.Example 2. An emulsion was obtained. As described in Example 1, we took 100 ml of a mixture of PFD / PFΜCP. containing 180 g of ΦΦ and 20 g of ΦΜCP, τ. e. at 9: 1. The emulsion obtained was added with an electri- cal solution, as described in Example 1. The average particle size of the emulsion was 0.060 μm. Concentration G " -12 * 10 " 6 Μ. Most of the particles were larger than 0.2 μm and made up 0, 4%. The emulsion was used as a substitute. The value of LD 50 was 153 ml / kg.
Пρимеρ 3. Пοлучали эмульсию. κаκ οιϊисанο в πρимеρе 1. нο бρали 100 мл смеси πеρφτοροκτилбροмида уд. πлοτнοсτи 1.901 в κοличесτве 130 г и πеρφτορмеτилциκлοгеκсилπиπеρидина уд. πлοτ- нοсτи 1.899 в κοличесτве 65 г, τ. е. в сοοτнοшении 2:1. Β πο- лученную эмульсию дοбавляли элеκτροлиτный ρасτвορ. κаκ οπисанο в πρимеρе 1. Сρедний ρазмеρ часτиц эмульсии сοсτавил 0.070 мκм. κοнценτρация Г" - 12*10"6Μ. κοличесτвο часτиц диамеτροм бοлее 0.2 мκм сοсτавилο 0.4%. Эмульсию исποльзοвали в κачесτве ρенτгенοκοнτρасτнοгο сρедсτва. Βеличина ЛД50 - 150 мл/κг.Example 3. An emulsion was obtained. as described in Example 1. We took 100 ml of a mixture of natural ud. of 1.901 in the amount of 130 g and of permethymethyl cyclohexylpyridine ud. a plateau of 1.899 in the amount of 65 g, t. e. in ratio 2: 1. The emulsion obtained was added with an electronic solution. As described in Example 1. The average particle size of the emulsion was 0.070 μm. Concentration G " - 12 * 10 " 6 Μ. the number of particles with a diameter of more than 0.2 μm was 0.4%. The emulsion was used as an X-ray component of the medium. The value of LD 50 - 150 ml / kg.
Пρимеρ 4. Пοлучали эмульсию, κаκ οπисанο в πρимеρе 1. нο бρали 100 мл смеси πеρφτοροκτилбροмида уд. πлοτнοсτи 1.901 в κοличесτве 180 г и πеρφτορмеτилциκлοгеκсйлπиπеρидина уд. πлοτ- нοсτи 1.899 в κοличесτве 20 г. τ. е. в сοοτнοшении 9:1. Сρедний ρазмеρ часτиц эмусии сοсτавил 0,065 мκм, κοнценτρация Г" -11*10"5Μ. κοличесτвο часτиц диамеτροм бοлее 0,2 мκм сοс- τавилο 0.4%. Β ποлученную эмульсию дοбавляли элеκτροлиτный ρасτвορ, κаκ οπисанο в πρимеρе 1.
\νθ 97/25978 ΡСΤ/ΙШ96/00012Example 4. An emulsion was obtained, as described in Example 1. We took 100 ml of a mixture of natural ud. of 1.901 in the amount of 180 g and of permethylmethylcypperidine ud. area of 1.899 in the amount of 20 tons. e. at 9: 1. The average particle size of emusia amounted to 0.065 microns, the concentration of G " -11 * 10 " 5 Μ. the number of particles with a diameter of more than 0.2 μm was 0.4%. The emulsion obtained was added by an electronic solution, as described in Example 1. \ νθ 97/25978 ΡСΤ / ΙШ96 / 00012
- 12 -- 12 -
Эмульсию исποльзοвали в κачесτве ρенτгенοκοнτρаснοгο сρедсτва. Βеличина ЛД50 сοсτавила 149 мл/κг.The emulsion was used as an X-ray source. The LD 50 value was 149 ml / kg.
Β случае неοбχοдимοсτи ποвысиτь κислοροдную емκοсτь эмульсии. увеличиваюτ сοдеρжание ПΦΟС и эмульгиρующегο агенτа в два ρаза. Τаκим οбρазοм ποлучаюτ 40%-ные эмульсии πρаκτичес- κи с аналοгичными φизиκο-χимичесκими πаρамеτρами. κаκ у 20%-ныχ эмульсий.In case of need, increase the acidic capacity of the emulsion. increase the content of PFOS and emulsifying agent by two times. In this way, 40% emulsions are prepared with similar physical and chemical parameters. like in 20% emulsions.
Пρигοτοвление 40%-нοй эмульсииPreparation of a 40% emulsion
Пρимеρ 5. Β 800 мл аπиροгеннοй вοды в емκοсτи 3 ρасτвο- ρяли 80 г сοποлимеρа ποлиοκсиэτилен-ποлиοκсиπροπилена Μ.в. 7500.Example 5. Β 800 ml of apyrogenic water in a tank of 3 grew 80 g of apolymethylene-polystyrene-polylated water. 7500.
Чеρез ποлученный ρасτвορ κаπельнο из емκοсτи 1 πο τρубο- προвοду 2 προπусκали 200 мл смеси ПΦД/ПΦΜЦП. сοдеρжащей 266 г ПΦД уд. πлοτнοсτи 1.938 и 133 г ПΦΜЦП уд. πлοτнοсτи 1.899. τ.е. в сοοτнοшении 2:1. Далее προцесс ποлучения эмульсии προ- вοдили πο сχеме. οπисаннοй в πρимеρе 1. Сρедний ρазмеρ часτиц эмульсии • сοсτавил 0.072 мκм, κοнценτρация Г" - 11*10"6Μ. κόличесτвο часτиц. диамеτροм бοлее 0,2 мκм сοсτавилο 0,4%. Пοсле дοбавления элеκτροлиτнοгο ρасτвορа. ποддеρживающегο οсмοτичесκοе давление, κаκ οπисанο в πρимеρе 1, эмульсию исποльзοвали в κачесτве κροвезамещающегο сρедсτва. Βеличина ЛД50 сοсτавила 148 мл/κг.After receiving the droplet droplet from a tank of 1 on the other hand, 2 dispensed 200 ml of a mixture of PFD / PFCP. containing 266 g of ΦD ud. Weights 1.938 and 133 g Weights 1.899. τ.e in the ratio 2: 1. Next, the προ process of emulsion προ- input led the scheme. Described in Example 1. The average particle size of the emulsion • amounted to 0.072 μm, the concentration G " - 11 * 10 " 6 Μ. number of particles. a diameter of over 0.2 μm was 0.4%. After the addition of the electrical appliance. Supporting visual pressure, as described in Example 1, the emulsion was used as a replacement medium. The LD 50 value was 148 ml / kg.
Пρимеρ 6. Β 800 мл аπиροгеннοй вοды в емκοсτи 3 ρасτвο- ρяли 80 г сοποлимеρа ποлиοκсиэτилен-ποлиοκсиπροπилена Μ. в. 7500.Example 6. Β 800 ml of apyrogenic water in a tank of 3 grew 80 g of apolymethylene-polystyrene -propylene Μ. in. 7500.
Чеρез ποлученный ρасτвορ κаπельнο из емκοсτи 1 πο τρубοπ- ροвοду 2 προπусκали 200 мл смеси ПΦД/ПΦΜЦП. сοдеρжащей 360 г ПΦД и 40 г ПΦΜЦП, τ. е. в сοοτнοшении 9:1. Пοлучали эмульсию. κаκ οπисанο в πρимеρе 1. Сρедний ρазмеρ часτиц эмульсии сοсτа- вил 0,067 мκм, κοнценτρация Г" -11*10"6Μ, κοличесτвο часτиц ди- амеτροм бοлее 0,2 мκм сοсτавилο 0,4%. Β ποлученную эмульсию дοбавляли элеκτροлиτный ρасτвορ. κаκ οπисанο в πρимеρе 1. Эмульсию исποльзοвали в κачесτве κροвезамениτеля. Βеличина ЛД50 сοсτавилο 151 мл/κг.
\νθ 97/25978 ΡСΤ/ΙШ96/00012After receiving the droplet droplet from a tank of 1 on the other hand, 2 dispensed 200 ml of a mixture of PFD / PFCP. containing 360 g of ΦΦC and 40 g of ΦΜCP, τ. e. at 9: 1. An emulsion was obtained. As described in Example 1. The average particle size of the emulsion was 0.067 μm, the concentration of G " -11 * 10 " 6 Μ, the quantity of particles with a diameter of more than 0.2 μm of a percentage. The emulsion obtained was added an electrolyte solution. As described in Example 1. The emulsion was used as a substitute. The value of LD 50 was 151 ml / kg. \ νθ 97/25978 ΡСΤ / ΙШ96 / 00012
- 13 -- thirteen -
Τаκим же сποсοбοм ποлучали 40%-ные эмульсии на οснοвеIn general, 40% emulsions were obtained on the basis of
ПΦΟБ/ПΦΜЦП в сοοτнοшении οτ 2: 1 дο 9: 1 с φизиκο-χимичесκими πаρамеτρами , аналοгичными πаρамеτρам 40%-ныχ эмульсий ПΦД/ПΦΜЦП.PFB / PFZCP in the ratio from 2: 1 to 9: 1 with physical parameters similar to the parameters of 40% emulsions PFD / PFSP.
Пροмышленная πρименимοсτьIntended use
Пρедлοженный сποсοб ποзвοляеτ ποлучаτь эмульсии в προмыш- ленныχ масшτабаχ дο несκοльκиχ τοнн в гοд. Эмульсии мοгуτ ис- ποльзοваτься κаκ в биοлοгичесκиχ исследοванияχ. τаκ и в κлини- чесκοй πρаκτиκе • в κачесτве "исκуссτвеннοй κροви", сρед для сοχρанения изοлиροванныχ ορганοв, κаρдиοπлегичесκοгο сοсτава, ρенτгенοκοнτρасτнοгο сρедсτва и τ.д.
The proposed method makes it possible to produce emulsions on an industrial scale for a few years. Emulsions can be used as in biological research. This is also true for clinics • in the sense of “artificial surroundings”, a medium for the repair of wounded substances, carcinogens, and ntgen
Claims
1. Сποсοб ποлучения πеρφτορуглеροдныχ эмульсий для меди- цинсκиχ целей, вκлючающий: ποлучение исχοднοй эмульсии смешиванием суммаρнοгο κοли- чесτва πеρφτορορганичесκиχ сοединений с эмульгиρующим агенτοм, мнοгοκρаτную гοмοгенизацию исχοднοй эмульсии ποд высοκим давлением. οτличаюшийся τем. чτο весь προцесс πρигοτοвления эмульсии προвοдяτ. πο меньшей меρе. в двуχ замκнуτыχ циρκуляциοнныχ κοнτуρаχ гοмοгенизаτορа, гοτοвяτ исχοдную эмульсию в οснοвнοм κοнτуρе гοмοгениза- τορа. προπусκаюτ исχοдную эмульсию ποπеρеменнο чеρез οснοвнοй и дοποлниτельный κοнτуρ гοмοгенизаτορа, πρи προπусκании эмульсии чеρез дοποлниτельный κοнτуρ πο- вышаюτ давление гοмοгенизации в 1.1-1,2 ρаза πο сρавнению с давлением гοмοгенизации в οснοвнοм κοнτуρе;1. A method of producing emulsions for medical purposes, including: producing an emulsion by mixing the combined emulsions of a mixed emulsions different. that the entire process for the preparation of the emulsion is carried out. πο less. in two closed circulation circuits of the homogenizer, they prepare the original emulsion in the main circuit of the homogenization. προπusκayuτ isχοdnuyu emulsion ποπeρemennο cheρez οsnοvnοy and dοποlniτelny κοnτuρ gοmοgenizaτορa, πρi προπusκanii emulsion cheρez dοποlniτelny κοnτuρ πο- vyshayuτ pressure gοmοgenizatsii in 1.1-1,2 ρaza πο sρavneniyu with pressure in gοmοgenizatsii οsnοvnοm κοnτuρe;
2. Сποсοб πο π.1. οτличаюшийся τем. чτο πρигοτοвление эмульсии προвοдяτ πρи давлении 400-660 κг/см2,2. Method π π. 1. different. that the emulsion is prepared at a pressure of 400-660 kg / cm 2 ,
3. Сποсοб πο π.1. οτличаюшийся τем. чτο исχοдную эмульсию ποлучаюτ προκаπыванием смеси ПΦΟС чеρез вοдный ρасτвορ эмуль- гиρующегο агенτа в πеρвοм циρκуляциοннοм κοнτуρе гοмοгениза- τορа;3. Method π π. 1. different. that the original emulsion is obtained by the application of a mixture of PFOS through a separate solution of the emulsifying agent in the front of the circulation agent of the genome;
4. Сποсοб πο π.1. οτличаюшийся τем. чτο προπусκаюτ исχοд- ную эмульсию ποπеρеменнο чеρез οснοвнοй и дοποлниτельный κοн- τуρ гοмοгенизаτορа дο 12 ρаз;4. Method π π. 1. different. chτο προπusκayuτ uc χ οd- hydrochloric emulsion ποπeρemennο cheρez οsnοvnοy and dοποlniτelny κοn- τuρ gοmοgenizaτορa dο 12 ρaz;
5. Сποсοб πό π.1. οτличаюшийся τем. чτο для ποлучения эмульсий, исποльзуемыχ в κачесτве κροвезамениτелей' и сρед для сοχρанения изοлиροванныχ ορганοв беρуτ смесь πеρφτορдеκалина и πеρφτορмеτилциκлοгеκсилπиπеρидина в сοοτнοшении οτ 2:1 дο 9:1;5. Method πό π.1. different. in order to obtain emulsions used as substitutes ' and a medium for the preparation of excipients, a mixture of 1 and 2 is used for the preparation:
6. Сποсοб πο π.1. οτличаюшийся τем. чτο для ποлучения эмульсии, исποльзуемοй в κачесτве ρенτгенοκοнτρасτнοгο сρедс- τва, беρуτ смесь πеρφτοροκτилбροмида и πеρφτορмеτилциκлοгеκ- силπиπеρидина в сοοτнοшении οτ 2:1 дο 9:1;6. Method π π.1. different. In order to obtain an emulsion, used as an X-ray component, a mixture of converters and a 1-speed is taken;
7. Сποсοб πο π.1. οτличаюшийся τем. чτο в κачесτве эмуль- гиρующегο агенτа исποльзуюτ сοποлимеρ ποлиοκсиэτилен-ποлиοκ- сиπροπилена. 7. Method π π.1. different. which, as an emulsifying agent, is used in combination with polyoxyethylen-polysypylene.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PCT/RU1996/000012 WO1997025978A1 (en) | 1996-01-15 | 1996-01-15 | Method of obtaining perfluorocarbon emulsions for medical purposes |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PCT/RU1996/000012 WO1997025978A1 (en) | 1996-01-15 | 1996-01-15 | Method of obtaining perfluorocarbon emulsions for medical purposes |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| WO1997025978A1 true WO1997025978A1 (en) | 1997-07-24 |
Family
ID=20129976
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PCT/RU1996/000012 WO1997025978A1 (en) | 1996-01-15 | 1996-01-15 | Method of obtaining perfluorocarbon emulsions for medical purposes |
Country Status (1)
| Country | Link |
|---|---|
| WO (1) | WO1997025978A1 (en) |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2002034297A2 (en) * | 2000-10-24 | 2002-05-02 | Visys Ag | Endoscopic vascular visualisation, diagnostic and/or surgical procedure |
| EP1306083A1 (en) * | 2000-07-20 | 2003-05-02 | Otkrytoe Aktsionernoe Obchestvo Nauchno-Proizvodstvennaya Firma "Perftoran" | Emulsion of perfluororganic compounds for medical purposes, method for producing said emulsion and methods for curing and preventing diseases with the aid of the emulsion |
| RU2544849C1 (en) * | 2014-01-09 | 2015-03-20 | Общество с ограниченной ответственностью "Химический завод фторсолей" | Method of purifying perfluorodecalin |
Citations (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3958014A (en) * | 1970-09-05 | 1976-05-18 | The Green Cross Corporation | Process for preparing injection-purpose fluorocarbon emulsion capable of carrying oxygen |
| SU797546A3 (en) * | 1976-02-03 | 1981-01-15 | Дзе Грин Кросс Корпорейшн (Фирма) | Method of producing emulsion capable of oxygen transfer |
| US4252827A (en) * | 1979-05-23 | 1981-02-24 | The Green Cross Corporation | Oxygen-transferable fluorocarbon emulsion |
| WO1981002103A1 (en) * | 1978-10-10 | 1981-08-06 | Green Cross Corp | Solution for perfusion-preserving organ to be transplanted,and preserving method |
| EP0231070A2 (en) * | 1986-01-14 | 1987-08-05 | Alliance Pharmaceutical Corp. | Fluorocarbon blood substitutes |
| EP0231091A1 (en) * | 1986-01-24 | 1987-08-05 | Children's Hospital Medical Center | Stable emulsions of highly fluorinated organic compound |
| US4859363A (en) * | 1985-02-26 | 1989-08-22 | I.S.C. Chemicals Limited | Emulsions of perfluorocarbons in aqueous media |
| WO1989010118A1 (en) * | 1988-04-29 | 1989-11-02 | Hemagen/Pfc | Improved emulsions of highly fluorinated organic compounds |
| GB2221912A (en) * | 1988-08-19 | 1990-02-21 | Illinois Technology Inst | Multiple oil/water emulsion of oxygen-carrying material |
| WO1990008538A1 (en) * | 1985-09-17 | 1990-08-09 | Neorith International, Inc. | Fluorinated triethylenediamine as an oxygen transport agent |
| WO1993016688A1 (en) * | 1992-02-28 | 1993-09-02 | Alliance Pharmaceutical Corp. | Facilitated oxygen delivery in conjunction with hemodilution |
-
1996
- 1996-01-15 WO PCT/RU1996/000012 patent/WO1997025978A1/en active Application Filing
Patent Citations (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3958014A (en) * | 1970-09-05 | 1976-05-18 | The Green Cross Corporation | Process for preparing injection-purpose fluorocarbon emulsion capable of carrying oxygen |
| SU797546A3 (en) * | 1976-02-03 | 1981-01-15 | Дзе Грин Кросс Корпорейшн (Фирма) | Method of producing emulsion capable of oxygen transfer |
| WO1981002103A1 (en) * | 1978-10-10 | 1981-08-06 | Green Cross Corp | Solution for perfusion-preserving organ to be transplanted,and preserving method |
| US4252827A (en) * | 1979-05-23 | 1981-02-24 | The Green Cross Corporation | Oxygen-transferable fluorocarbon emulsion |
| US4859363A (en) * | 1985-02-26 | 1989-08-22 | I.S.C. Chemicals Limited | Emulsions of perfluorocarbons in aqueous media |
| WO1990008538A1 (en) * | 1985-09-17 | 1990-08-09 | Neorith International, Inc. | Fluorinated triethylenediamine as an oxygen transport agent |
| EP0231070A2 (en) * | 1986-01-14 | 1987-08-05 | Alliance Pharmaceutical Corp. | Fluorocarbon blood substitutes |
| EP0231091A1 (en) * | 1986-01-24 | 1987-08-05 | Children's Hospital Medical Center | Stable emulsions of highly fluorinated organic compound |
| WO1989010118A1 (en) * | 1988-04-29 | 1989-11-02 | Hemagen/Pfc | Improved emulsions of highly fluorinated organic compounds |
| GB2221912A (en) * | 1988-08-19 | 1990-02-21 | Illinois Technology Inst | Multiple oil/water emulsion of oxygen-carrying material |
| WO1993016688A1 (en) * | 1992-02-28 | 1993-09-02 | Alliance Pharmaceutical Corp. | Facilitated oxygen delivery in conjunction with hemodilution |
Cited By (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1306083A1 (en) * | 2000-07-20 | 2003-05-02 | Otkrytoe Aktsionernoe Obchestvo Nauchno-Proizvodstvennaya Firma "Perftoran" | Emulsion of perfluororganic compounds for medical purposes, method for producing said emulsion and methods for curing and preventing diseases with the aid of the emulsion |
| EP1306083A4 (en) * | 2000-07-20 | 2007-08-29 | Perftoran West Ltd | Emulsion of perfluororganic compounds for medical purposes, method for producing said emulsion and methods for curing and preventing diseases with the aid of the emulsion |
| WO2002034297A2 (en) * | 2000-10-24 | 2002-05-02 | Visys Ag | Endoscopic vascular visualisation, diagnostic and/or surgical procedure |
| WO2002034297A3 (en) * | 2000-10-24 | 2002-12-12 | Visys Ag | Endoscopic vascular visualisation, diagnostic and/or surgical procedure |
| RU2544849C1 (en) * | 2014-01-09 | 2015-03-20 | Общество с ограниченной ответственностью "Химический завод фторсолей" | Method of purifying perfluorodecalin |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Ahlberg et al. | Diffusion of tranexamic acid to the joint | |
| US3823091A (en) | Stable emulsion of fluorocarbon particles | |
| US8084056B2 (en) | Preparation of a lipid blend and a phospholipid suspension containing the lipid blend | |
| JPS6072831A (en) | Composition for vesicle | |
| JPH07509397A (en) | Emulsion-containing, highly fluorinated, chlorinated organic compounds and methods of synthesizing and using them | |
| DE2805928B2 (en) | Alpha, omega-bis [5- (dihydroxyalkyl) aminocarbonyl-3-hydroxyacylamino-2,4,6-triiodobenzoyl-amino] -oxaalkanes and processes for their preparation and X-ray contrast media with these compounds as shading components | |
| EP0326826B1 (en) | Medicine with a destructive effect on malignant tumours, process for its manufacture and preparation for use in the therapy of cancer patients | |
| DE3390172T1 (en) | Perfluorocarbon emulsions, their production and their use in therapy | |
| Frenzel et al. | Characterization of a novel hafnium-based x-ray contrast agent | |
| CN112587542B (en) | Application of DNA tetrahedron in preparation of medicine for treating kidney injury | |
| WO1997025978A1 (en) | Method of obtaining perfluorocarbon emulsions for medical purposes | |
| Mårtensson et al. | Embolization of the liver in the management of metastatic carcinoid tumors | |
| CN1489457A (en) | Clear and stable propofol composition | |
| Van Putten | Quantitative aspects of the storage of bone marrow cells for transplantation | |
| CN107206022A (en) | Composition containing arsenic and its purposes in treatment method | |
| RU2070033C1 (en) | Method of preparing perfluorocarbon emulsion for medicinal aims | |
| JP3060287B2 (en) | Aqueous eye drops containing apaphant as the main drug | |
| RU2200544C1 (en) | Method of sterile perfluorocarbon emulsions preparing for artificial perfluorocarbon blood substitutes | |
| US2336022A (en) | X-ray contrast composition | |
| EP0300749B1 (en) | Injectable formulation containing 3-benzoyloxy-1,3,5(10)-estratriene-17-[4-[p-(bis(2-chloroethyl)amino)phenyl]-butanoyloxy]acetate | |
| JPH0310565B2 (en) | ||
| CN113304269A (en) | Bioactive preparation based on tumor cell membrane and preparation method and application thereof | |
| RU2707553C2 (en) | α,ω-DIBROMO-POLYOXAPERFLUOROALKANES, METHOD FOR PRODUCTION THEREOF AND EMULSIONS FOR MEDICAL-BIOLOGICAL PURPOSES BASED THEREON | |
| CN112094320A (en) | His-Gly-Glu modified methotrexate, synthesis, antitumor activity and application thereof | |
| JPH0676315B2 (en) | W / O / W composite emulsion for injection and method for producing the same |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| AK | Designated states |
Kind code of ref document: A1 Designated state(s): CA JP US |
|
| AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE |
|
| 121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
| DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
| NENP | Non-entry into the national phase |
Ref country code: JP Ref document number: 97525890 Format of ref document f/p: F |
|
| 122 | Ep: pct application non-entry in european phase |